Osiris Therapeutics (OSIR) Trades Strong Following Prochymal News; Shares Nearly at Annual Highs
Tweet
Share
E-mailGet Alerts OSIR Hot Sheet
Join SI Premium – FREE
Osiris Therapeutics, Inc. (Nasdaq: OSIR) shares are moving today on strong volume following an earlier announcement it received consent from New Zealand to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.
Volatility on the stock is up 22 points from Wednesday to 96.85 percent.
Shares are up over 11 percent on the session. Earlier, shares were inching closer to a fresh 52-week high at $8.39. Today is actually the highest level shares have been since last July.
Volatility on the stock is up 22 points from Wednesday to 96.85 percent.
Shares are up over 11 percent on the session. Earlier, shares were inching closer to a fresh 52-week high at $8.39. Today is actually the highest level shares have been since last July.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana (HUM) surges on Q1 beat, reiterated adjusted earnings outlook
- Alphabet (GOOG) call put ratio 4.2 calls to 1 put into quarter results
- Texas Instruments (TXN) jumps on first above-consensus guide in seven years
Create E-mail Alert Related Categories
Insiders' Blog, OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
